Author Correction: Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1

Nat Immunol. 2020 Jun;21(6):695. doi: 10.1038/s41590-020-0640-6.

Michael D Crowther^#¹, Garry Dolton^#¹, Mateusz Legut¹, Marine E Caillaud¹, Angharad Lloyd¹, Meriem Attaf¹, Sarah A E Galloway¹, Cristina Rius¹, Colin P Farrell², Barbara Szomolay^{1

3}, Ann Ager^{1

3}, Alan L Parker⁴, Anna Fuller¹, Marco Donia⁵, James McCluskey⁶, Jamie Rossjohn^{1

3

7

8}, Inge Marie Svane⁵, John D Phillips², Andrew K Sewell^{9

10}

¹ Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
² Division of Hematology, University of Utah School of Medicine, Salt Lake City, UT, USA.
³ Systems Immunity Research Institute, Cardiff University, Cardiff, UK.
⁴ Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK.
⁵ Center for Cancer Immune Therapy, Herlev Hospital, Copenhagen University, Copenhagen, Denmark.
⁶ Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia.
⁷ Australian Research Council Centre of Excellence in Advanced Molecular Imaging, Monash University, Clayton, Victoria, Australia.
⁸ Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
⁹ Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK. sewellak@cardiff.ac.uk.
¹⁰ Systems Immunity Research Institute, Cardiff University, Cardiff, UK. sewellak@cardiff.ac.uk.

^# Contributed equally.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.